{"id":"lesinurad","rwe":[{"pmid":"41631245","year":"2026","title":"A novel method for screening antihyperuricemic drugs by combining aptamer sensor array, exonuclease III-DNA walker and linear discriminant analysis.","finding":"","journal":"Journal of pharmaceutical analysis","studyType":"Clinical Study"},{"pmid":"41282962","year":"2025","title":"Decoding gout pathogenesis: target discovery and drug design through computational models.","finding":"","journal":"In silico pharmacology","studyType":"Clinical Study"},{"pmid":"41165601","year":"2026","title":"Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies.","finding":"","journal":"Rheumatology (Oxford, England)","studyType":"Clinical Study"},{"pmid":"40809993","year":"2025","title":"Serum uric acid, renal status, cardiovascular-kidney-metabolic syndrome and drug therapy, a wide-angled Mendelian randomization analysis.","finding":"","journal":"American heart journal plus : cardiology research and practice","studyType":"Clinical Study"},{"pmid":"40790034","year":"2025","title":"Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.","finding":"","journal":"Nature communications","studyType":"Clinical Study"}],"tags":[{"label":"Urate Transporter 1 Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 22 member 11","category":"target"},{"label":"SLC22A11","category":"gene"},{"label":"SLC22A12","category":"gene"},{"label":"M04AB05","category":"atc"},{"label":"LOE Approaching","category":"status"},{"label":"Hyperuricemia","category":"indication"},{"label":"Ironwood Pharms Inc","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Gout Suppressants","category":"pharmacology"},{"label":"Uricosuric Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Ironwood Pharms Inc","patents":[{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Aug 17, 2029","useCode":"U-1801","territory":"US","drugProduct":false,"patentNumber":"8084483","drugSubstance":false},{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Nov 26, 2028","useCode":"U-1804","territory":"US","drugProduct":false,"patentNumber":"8283369","drugSubstance":false},{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Dec 22, 2029","useCode":"U-1801","territory":"US","drugProduct":true,"patentNumber":"8357713","drugSubstance":false},{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Dec 28, 2031","useCode":"U-2311","territory":"US","drugProduct":false,"patentNumber":"9956205","drugSubstance":false},{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Nov 26, 2028","useCode":"U-2311","territory":"US","drugProduct":false,"patentNumber":"10183012","drugSubstance":false},{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Apr 29, 2029","useCode":"U-1803","territory":"US","drugProduct":false,"patentNumber":"8546437","drugSubstance":false},{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Aug 1, 2031","useCode":"U-1806","territory":"US","drugProduct":false,"patentNumber":"9216179","drugSubstance":false},{"applNo":"N207988","source":"FDA Orange Book","status":"Active","expires":"Feb 29, 2032","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8546436","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LESINURAD","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:22:08.045383+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:22:08.045283+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Lesinurad","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:22:15.437849+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:22:13.998625+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:22:08.118503+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LESINURAD","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:22:14.354845+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Solute carrier family 22 member 12 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:22:15.437782+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105720/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:22:15.083152+00:00"}},"allNames":"zurampic","offLabel":[],"synonyms":["lesinurad","zurampic","RDEA594 Sodium","RDEA594"],"timeline":[{"date":"2015-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ARDEA BIOSCIENCES INC to Ironwood Pharms Inc"},{"date":"2015-12-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Ardea Biosciences Inc)"},{"date":"2016-02-18","type":"positive","source":"DrugCentral","milestone":"EMA approval (AstraZeneca AB)"},{"date":"2032-02-29","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8546436 expires"}],"approvals":[{"date":"2015-12-22","orphan":false,"company":"ARDEA BIOSCIENCES INC","regulator":"FDA"},{"date":"2016-02-18","orphan":false,"company":"AstraZeneca AB","regulator":"EMA"}],"brandName":"Zurampic","ecosystem":[{"indication":"Hyperuricemia","otherDrugs":[{"name":"allopurinol","slug":"allopurinol","company":"Prometheus Labs"},{"name":"febuxostat","slug":"febuxostat","company":"Takeda Pharms Usa"},{"name":"probenecid","slug":"probenecid","company":""},{"name":"rasburicase","slug":"rasburicase","company":"Sanofi Synthelabo"}],"globalPrevalence":null}],"mechanism":{"target":"Solute carrier family 22 member 11","novelty":"Follow-on","targets":[{"gene":"SLC22A11","source":"DrugCentral","target":"Solute carrier family 22 member 11","protein":"Solute carrier family 22 member 11"},{"gene":"SLC22A12","source":"DrugCentral","target":"Solute carrier family 22 member 12","protein":"Solute carrier family 22 member 12"}],"moaClass":"Cytochrome P450 3A Inducers","modality":"Small Molecule","drugClass":"Urate Transporter 1 Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Zurampic inhibits the urate transporter 1 (URAT1), a member of the solute carrier family 22, to decrease the reabsorption of uric acid in the kidneys and increase its excretion in the urine."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Lesinurad","title":"Lesinurad","extract":"Lesinurad is a urate transporter inhibitor for treating high blood uric acid levels associated with gout. It is recommended only as an adjuvant with either allopurinol or febuxostat when these medications are not sufficient."},"commercial":{"launchDate":"2015","_launchSource":"DrugCentral (FDA 2015-12-22, ARDEA BIOSCIENCES INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5075","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LESINURAD","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LESINURAD","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Lesinurad","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T12:17:35.844143","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:22:16.805130+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"probenecid","drugSlug":"probenecid","fdaApproval":"1951-04-26","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sulfinpyrazone","drugSlug":"sulfinpyrazone","fdaApproval":"1959-05-13","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"lesinurad","indications":{"approved":[{"name":"Hyperuricemia","source":"DrugCentral","snomedId":35885006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Ironwood Pharms Inc","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"probenecid","brandName":"probenecid","genericName":"probenecid","approvalYear":"1951","relationship":"same-class"},{"drugId":"sulfinpyrazone","brandName":"sulfinpyrazone","genericName":"sulfinpyrazone","approvalYear":"1959","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03226899","phase":"PHASE4","title":"A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment","status":"TERMINATED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2017-07-19","conditions":["Gout","Chronic Kidney Disease (CKD)"],"enrollment":242,"completionDate":"2019-02-25"},{"nctId":"NCT04072471","phase":"","title":"Post-Authorisation Safety Study of Lesinurad","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2021-01-29","conditions":["Gout","Hyperuricemia"],"enrollment":0,"completionDate":"2023-06-30"},{"nctId":"NCT03272425","phase":"PHASE1","title":"Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2017-08-14","conditions":["Gout"],"enrollment":32,"completionDate":"2017-10-04"},{"nctId":"NCT01808144","phase":"PHASE3","title":"Lesinurad and Febuxostat Combination Extension Study in Gout","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2013-03-01","conditions":["Gout"],"enrollment":196,"completionDate":"2016-10-06"},{"nctId":"NCT02888054","phase":"PHASE1","title":"Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2016-08-30","conditions":["Healthy"],"enrollment":28,"completionDate":"2017-02-01"},{"nctId":"NCT01001338","phase":"PHASE2","title":"Allopurinol Combination Study","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2009-10","conditions":["Gout"],"enrollment":227,"completionDate":"2016-08"},{"nctId":"NCT01808131","phase":"PHASE3","title":"Lesinurad and Allopurinol Combination Extension Study in Gout","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2013-02","conditions":["Gout"],"enrollment":717,"completionDate":"2016-11"},{"nctId":"NCT02581553","phase":"PHASE1","title":"Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2015-10","conditions":["Healthy"],"enrollment":116,"completionDate":"2016-08"},{"nctId":"NCT01510158","phase":"PHASE3","title":"Combining Lesinurad With Allopurinol in Inadequate Responders","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2012-01","conditions":["Gout"],"enrollment":607,"completionDate":"2014-08"},{"nctId":"NCT01650246","phase":"PHASE3","title":"Open-Label Lesinurad Monotherapy Extension Study in Gout","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2012-08","conditions":["Gout"],"enrollment":143,"completionDate":"2014-08"},{"nctId":"NCT01510769","phase":"PHASE3","title":"Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2012-01","conditions":["Tophaceous Gout"],"enrollment":330,"completionDate":"2014-06"},{"nctId":"NCT01493531","phase":"PHASE3","title":"Combining Lesinurad With Allopurinol in Inadequate Responders","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2011-12","conditions":["Gout"],"enrollment":610,"completionDate":"2014-07"},{"nctId":"NCT01508702","phase":"PHASE3","title":"Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2012-01","conditions":["Gout"],"enrollment":214,"completionDate":"2013-11"},{"nctId":"NCT02127775","phase":"PHASE1","title":"Lesinurad Tablet Bioequivalence","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2014-04","conditions":["Healthy"],"enrollment":54,"completionDate":"2014-07"},{"nctId":"NCT01986556","phase":"PHASE1","title":"Lesinurad Tablet Relative Bioavailability","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2013-11","conditions":["Healthy"],"enrollment":36,"completionDate":"2014-05"},{"nctId":"NCT02039700","phase":"PHASE1","title":"Bioavailability of Lesinurad and Intravenous [14C]Lesinurad","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2014-01","conditions":["Healthy"],"enrollment":10,"completionDate":"2014-04"},{"nctId":"NCT01982201","phase":"PHASE1","title":"Antacid Interaction Study","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2013-11","conditions":["Healthy"],"enrollment":24,"completionDate":"2014-03"},{"nctId":"NCT00955981","phase":"PHASE2","title":"Gout Dose Response Study","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2009-07","conditions":["Hyperuricemia"],"enrollment":123,"completionDate":"2011-09"},{"nctId":"NCT02028689","phase":"PHASE1","title":"Metformin and Furosemide Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2013-10","conditions":["Healthy"],"enrollment":23,"completionDate":"2014-01"},{"nctId":"NCT01908257","phase":"PHASE1","title":"Lesinurad Interaction Study With Ranitidine","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2013-07","conditions":["Healthy"],"enrollment":16,"completionDate":"2013-11"},{"nctId":"NCT01884272","phase":"PHASE1","title":"NSAID Drug Interaction Study","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2013-06","conditions":["Gout"],"enrollment":24,"completionDate":"2013-10"},{"nctId":"NCT01744379","phase":"PHASE1","title":"Single and Multiple Dose Study in Japanese","status":"COMPLETED","sponsor":"Ardea Biosciences, Inc.","startDate":"2012-12","conditions":["Gout"],"enrollment":40,"completionDate":"2013-05"}],"_emaApprovals":[{"date":"2016-02-18","status":"Authorised","company":"AstraZeneca AB"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"237601","NDDF":"016642","UNII":"09ERP08I3W","CHEBI":"CHEBI:90929","VANDF":"4036022","INN_ID":"9345","RXNORM":"1731031","UMLSCUI":"C3886073","chemblId":"CHEMBL2105720","ChEMBL_ID":"CHEMBL2105720","KEGG_DRUG":"D09921","DRUGBANK_ID":"DB11560","PUBCHEM_CID":"53465279","SNOMEDCT_US":"715259003","IUPHAR_LIGAND_ID":"7673","MESH_SUPPLEMENTAL_RECORD_UI":"C000593471"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2015-","companyName":"Ardea Biosciences Inc","relationship":"Original Developer"},{"period":"present","companyName":"Ironwood Pharms Inc","relationship":"Current Owner"},{"period":"2016","companyName":"AstraZeneca","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.0 hours","clearance":"1.43 mL/min/kg","fractionUnbound":"0.02%","volumeOfDistribution":"0.29 L/kg"},"publicationCount":168,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"M04AB05","allCodes":["M04AB05"]},"biosimilarFilings":[],"originalDeveloper":"Ardea Biosciences Inc","recentPublications":[{"date":"2026 Jan","pmid":"41631245","title":"A novel method for screening antihyperuricemic drugs by combining aptamer sensor array, exonuclease III-DNA walker and linear discriminant analysis.","journal":"Journal of pharmaceutical analysis"},{"date":"2025","pmid":"41282962","title":"Decoding gout pathogenesis: target discovery and drug design through computational models.","journal":"In silico pharmacology"},{"date":"2026 Feb 4","pmid":"41165601","title":"Incidence and risk of nephrolithiasis with uricosuric therapies for the treatment of gout: a systematic review and meta-analysis of randomized controlled trials and cohort studies.","journal":"Rheumatology (Oxford, England)"},{"date":"2025 Sep","pmid":"40809993","title":"Serum uric acid, renal status, cardiovascular-kidney-metabolic syndrome and drug therapy, a wide-angled Mendelian randomization analysis.","journal":"American heart journal plus : cardiology research and practice"},{"date":"2025 Aug 12","pmid":"40790034","title":"Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.","journal":"Nature communications"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Ironwood Pharms Inc","companyId":"ironwood-pharms-inc","modality":"Small molecule","firstApprovalDate":"2015","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-22T00:00:00.000Z","mah":"ARDEA BIOSCIENCES INC","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2015-12-22T00:00:00.000Z","mah":"ARDEA BIOSCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2015-12-22T00:00:00.000Z","mah":"ARDEA BIOSCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2015-12-22T00:00:00.000Z","mah":"ARDEA BIOSCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2015-12-22T00:00:00.000Z","mah":"ARDEA BIOSCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2015-12-22T00:00:00.000Z","mah":"ARDEA BIOSCIENCES INC","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:22:16.805130+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}